收费全文 | 2413262篇 |
免费 | 199354篇 |
国内免费 | 4251篇 |
耳鼻咽喉 | 34795篇 |
儿科学 | 74175篇 |
妇产科学 | 64015篇 |
基础医学 | 340830篇 |
口腔科学 | 69131篇 |
临床医学 | 218884篇 |
内科学 | 473020篇 |
皮肤病学 | 49079篇 |
神经病学 | 205227篇 |
特种医学 | 98149篇 |
外国民族医学 | 892篇 |
外科学 | 365924篇 |
综合类 | 56400篇 |
一般理论 | 1039篇 |
预防医学 | 195284篇 |
眼科学 | 56240篇 |
药学 | 180705篇 |
4篇 | |
中国医学 | 4399篇 |
肿瘤学 | 128675篇 |
2018年 | 25207篇 |
2017年 | 19691篇 |
2016年 | 21556篇 |
2015年 | 24459篇 |
2014年 | 35390篇 |
2013年 | 53242篇 |
2012年 | 72643篇 |
2011年 | 76146篇 |
2010年 | 44527篇 |
2009年 | 42956篇 |
2008年 | 72120篇 |
2007年 | 76557篇 |
2006年 | 77297篇 |
2005年 | 75093篇 |
2004年 | 71991篇 |
2003年 | 69374篇 |
2002年 | 68467篇 |
2001年 | 113691篇 |
2000年 | 117544篇 |
1999年 | 98897篇 |
1998年 | 26827篇 |
1997年 | 24312篇 |
1996年 | 24207篇 |
1995年 | 24915篇 |
1994年 | 23457篇 |
1993年 | 21835篇 |
1992年 | 80079篇 |
1991年 | 77088篇 |
1990年 | 74205篇 |
1989年 | 71438篇 |
1988年 | 66356篇 |
1987年 | 65308篇 |
1986年 | 61821篇 |
1985年 | 58893篇 |
1984年 | 44553篇 |
1983年 | 37925篇 |
1982年 | 23015篇 |
1981年 | 20421篇 |
1979年 | 41562篇 |
1978年 | 29141篇 |
1977年 | 24405篇 |
1976年 | 22816篇 |
1975年 | 24002篇 |
1974年 | 29699篇 |
1973年 | 28138篇 |
1972年 | 26332篇 |
1971年 | 24296篇 |
1970年 | 22837篇 |
1969年 | 21174篇 |
1968年 | 19217篇 |
Vaccination prevents severe morbidity and mortality from COVID-19 in the general population. The immunogenicity and efficacy of SARS-CoV-2 vaccines in patients with antibody deficiency is poorly understood.
ObjectivesCOVID-19 in patients with antibody deficiency (COV-AD) is a multi-site UK study that aims to determine the immune response to SARS-CoV-2 infection and vaccination in patients with primary or secondary antibody deficiency, a population that suffers from severe and recurrent infection and does not respond well to vaccination.
MethodsIndividuals on immunoglobulin replacement therapy or with an IgG less than 4 g/L receiving antibiotic prophylaxis were recruited from April 2021. Serological and cellular responses were determined using ELISA, live-virus neutralisation and interferon gamma release assays. SARS-CoV-2 infection and clearance were determined by PCR from serial nasopharyngeal swabs.
ResultsA total of 5.6% (n?=?320) of the cohort reported prior SARS-CoV-2 infection, but only 0.3% remained PCR positive on study entry. Seropositivity, following two doses of SARS-CoV-2 vaccination, was 54.8% (n?=?168) compared with 100% of healthy controls (n?=?205). The magnitude of the antibody response and its neutralising capacity were both significantly reduced compared to controls. Participants vaccinated with the Pfizer/BioNTech vaccine were more likely to be seropositive (65.7% vs. 48.0%, p?=?0.03) and have higher antibody levels compared with the AstraZeneca vaccine (IgGAM ratio 3.73 vs. 2.39, p?=?0.0003). T cell responses post vaccination was demonstrable in 46.2% of participants and were associated with better antibody responses but there was no difference between the two vaccines. Eleven vaccine-breakthrough infections have occurred to date, 10 of them in recipients of the AstraZeneca vaccine.
ConclusionSARS-CoV-2 vaccines demonstrate reduced immunogenicity in patients with antibody deficiency with evidence of vaccine breakthrough infection.
相似文献